Tag: control

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed

MADRID, 25 July 2025 – Neinor Homes (“Neinor”) (HOME SM), the leading residential platform in Spain, has announced its results for the first half of 2025, confirming the continued growth of its Asset Management business, solid operating margins, and a record commercialization activity. The period also marks an acceleration in the Company’s investment strategy with the launch of a voluntary tender offer for 100% of Aedas Homes’ capital.

HONOLULU, July 25, 2025 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ:FHB), (“First Hawaiian” or the “Company”) today reported financial results for its quarter ended June 30, 2025.

ZEELAND, Mich., July 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three and six months ended June 30, 2025.

Orrön Energy AB (“Orrön Energy”) will publish its financial report for the second quarter 2025 on Wednesday, 6 August 2025 at 07:30 CEST, followed by a webcast at 14:00 CEST.

Learn about JackBit Casino, named leading Crypto Casino of 2025. Enjoy instant payouts, 6000+ games, live sports betting, 24/7 support, and more. 

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Press release
Embargo until 25 July 2025 at 6:50 am
 Regulated information – Inside information